[123I]-metaiodobenzylguanidine imaging findings and outcome in patients with metastatic neuroblastoma

SA Journal of Oncology

Field Value
Title [123I]-metaiodobenzylguanidine imaging findings and outcome in patients with metastatic neuroblastoma
Creator Amoako, Yaw A. van Eyssen, Ann Brink, Anita
Subject Nuclear Medicine; Paediatric Oncology neuroblastoma; baseline; Curie score; [123I]mIBG; post-induction Curie score; overall survival
Description Background: 123I-Metaiodobenzylguanidine ([123I]mIBG) is the agent of choice to assess for presence of metastases and therapy response in patients with neuroblastoma.Aim: To assess [123I]mIBG scan results and outcome in patients with stage 4 neuroblastoma at our institution.Setting: Red Cross War Memorial Children’s Hospital.Methods: A retrospective review of baseline and follow-up [123I]mIBG scans of patients who presented between January 2001 and May 2015. The clinical follow up extended until October 2019. The association between the baseline and post-induction Curie score (CS) and overall survival (OS) were assessed.Results: Thirty-four patients with stage 4 disease were included. Twenty-two (65%) patients died. The median age at diagnosis for survivors was 15.5 months vs 39 months for those who died (Kruskal Wallis c2 = 4.63, p = 0.03). Neither the baseline CS nor the post-induction CS predict the outcome or duration of survival. The median OS for a baseline CS ≤ 12 and CS 12 was 19 and 26 months, p = 0.13. The median OS for a post-induction CS 2 and CS ≤ 2 was 28 and 26 months, p = 0.66.Conclusion: In this study, baseline, post-induction and reduction in CS did not predict OS in stage 4 neuroblastoma. Factors such as small patient numbers, less intensive treatment regimes, and possible poorly dedifferentiated disease have been identified for this finding.Contribution: In contrast to international studies the Curie score did not predict treatment outcome in the South African setting where the vast majority of patients are treated with OPEC/OJEC OPEC/OJEC (vincristine [O], cisplatin [P], etoposide [E], cyclophosphamide [C] and carboplatin [J]) chemotherapy. 
Publisher AOSIS
Contributor None
Date 2023-03-06
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — Qualitative research
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/sajo.v7i0.250
Source South African Journal of Oncology; Vol 7 (2023); 6 pages 2523-0646 2518-8704
Language eng
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://sajo.org.za/index.php/sajo/article/view/250/727 https://sajo.org.za/index.php/sajo/article/view/250/728 https://sajo.org.za/index.php/sajo/article/view/250/729 https://sajo.org.za/index.php/sajo/article/view/250/730
Coverage South Africa 2001-2019 Children
Rights Copyright (c) 2023 Yaw A. Amoako, Ann van Eyssen, Anita Brink https://creativecommons.org/licenses/by/4.0